Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors

NCT01341834 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour

Interventions

DRUG: LBH589 and RAD001

Sponsor

National Cancer Centre, Singapore

Collaborators

[object Object]